BioNTech, Pfizer Begin German Part of COVID-19 Vaccine Study BioNTech, Pfizer Begin German Part of COVID-19 Vaccine Study
Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
More News: Biotechnology | COVID-19 | Germany Health | Infectious Diseases | Intensive Care | Pfizer | Study | Vaccines